Current Edition:

Table of Contents

Editor's Note
Neil Love, MD

Summary and implications of ATAC trial results


Reduction in contralateral breast cancers


Safety profile of anastrozole


Bisphosphonates combined with anastrozole

  Neoadjuvant use of aromatase inhibitors
  The value of screening mammography
References on aromatase inhibitors in breast cancer management and the value of screening mammography
Mark Pegram, MD
Overview of HER2 biology and evaluation of HER2 assays
  Mechanism of antitumor action of trastuzumab
  Management of HER2-positive patients
  Duration and scheduling of trastuzumab treatment
  Hormonal therapy in combination with trastuzumab
  Trastuzumab in the adjuvant setting
References on the assessment of HER2 and the role of trastuzumab in the adjuvant and metastatic setting
Robert Livingston, MD
Proposed Intergroup adjuvant study of AC followed by docetaxel +/- capecitabine
  Capecitabine/docetaxel (XT) combination in clinical practice
  Clinical trials of antitubulin combinations
  Treatment algorithm for HER2-positive/negative metastatic breast cancer
  Combination versus single agent chemotherpy for advanced disease
  Duration of trastuzumab therapy
  PET scanning with labeled estrogens
References on metronomic dosing of chemotherapy; capecitabine and docetaxel alone or in combination for metastatic breast cancer; PET imaging of estrogen receptors






Home · Contact us
Terms of use and general disclaimer
© NL Communications, Inc. 2003. All rights reserved.